In general , stimulants improved driving performance in ADHD patients ( either in RCTs conducted in simulators and /or cars ) .
MPH-OROS  improved driving performance compared with MAS-XR , placebo , or no-drug conditions .
Although MPH-OROS and MPH-IR produced similar improvements during the day , MPH-IR lost its efficacy in the evening .
MAS-XR also improved driving performance , but worsened driving performance in the evening .
Studies with ATX report conflicting results .
Improvement was more consistent in teenagers and young adults .
In general , treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients .
To conclude , treatment with stimulants in therapeutic doses improves driving performance in ADHD patients , especially teenagers and young adults
Adults with Attention Deficit Hyperactivity Disorder ( ADHD ) , especially teenagers and young adults , show important car driving impairments , including risky driving , accidents , fines and suspension of driver׳s license .
We systematic ally review ed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients .
The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm.
Young adults with Attention Deficit Hyperactivity Disorder ( ADHD ) have been shown to be at increased risk for impairment in driving behaviors . While stimulant medications have proven efficacy in reducing ADHD symptomatology , there is limited knowledge as to their effects on driving impairment . The main aim of this study was to assess the impact of lisdexamfetamine dimesylate ( LDX ) on driving performance in young adults with ADHD using a vali date d driving simulation paradigm . This was a r and omized , double-blind , 6-week , placebo-controlled , parallel- design study of LDX vs. a placebo on driving performance in a vali date d driving simulation paradigm . Subjects were sixty-one out patients of both sexes , 18 - 26 years of age , who met DSM-IV criteria for ADHD . Subjects were r and omized to receive LDX or placebo after a baseline driving simulation and completed a second driving simulation six weeks after beginning drug or placebo . Examination of reaction time across five surprise events at post-treatment showed a significant positive effect of medication status . LDX treatment was also associated with significantly fewer accidents vs. placebo . LDX treatment was associated with significantly faster reaction times and a lower rate of simulated driving collisions than placebo . These results suggest that LDX may reduce driving risks in young adults with ADHD
In general , stimulants improved driving performance in ADHD patients ( either in RCTs conducted in simulators and /or cars ) .
MPH-OROS  improved driving performance compared with MAS-XR , placebo , or no-drug conditions .
Although MPH-OROS and MPH-IR produced similar improvements during the day , MPH-IR lost its efficacy in the evening .
MAS-XR also improved driving performance , but worsened driving performance in the evening .
Studies with ATX report conflicting results .
Improvement was more consistent in teenagers and young adults .
In general , treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients .
To conclude , treatment with stimulants in therapeutic doses improves driving performance in ADHD patients , especially teenagers and young adults
Adults with Attention Deficit Hyperactivity Disorder ( ADHD ) , especially teenagers and young adults , show important car driving impairments , including risky driving , accidents , fines and suspension of driver׳s license .
We systematic ally review ed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients .